## Health Partners •••• Medicare

## PRIOR AUTHORIZATION REQUEST FORM

Ingrezza - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.	
Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
ine of Business:   Medicare	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):
he life or health of the enrollee or the enrollee's ability to regain maximum functi  Drug Name:	certify that applying the 72 hour standard review timeframe may seriously jeopardize on.
Strength: Directions / SIG:	
Directions / Gro.	
Please attach any pertinent medical history including labs and information for this member that may support approval.	
Please answer the following questions and sign.	
Q1. Is this a request for continuation of therapy with Ingre	_
Yes	□ No
Q2. Has the patient been approved for treatment with Ingrezza?	
☐ Yes	□ No
Q3. Does the patient have a documented improvement in symptoms related to tardive dyskinesia with an updated Abnormal Involuntary Movement Scale (AIMS) assessment attached?	
☐ Yes	□No
Q4. Is the patient 18 years of age or older?	
☐Yes	□ No
Q5. Is Ingrezza being requested by or in consultation with a neurologist or psychiatrist?	
☐ Yes	□No
Q6. Has the patient been diagnosed with tardive dyskinesia and has a copy of the Abnormal Involuntary Movement Scale (AIMS) assessment been attached?	
☐ Yes	□No
Q7. Is there documentation that other movement disorders (such as Parkinson's disease, chorea associated with Huntington's disease) have been excluded?	
☐ Yes	□No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## PRIOR AUTHORIZATION REQUEST FORM

Ingrezza - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Q8. Does the patient have documentation of current or former chronic use of a dopamine antagonist (e.g., antipsychotic [first or second generation], metoclopramide, prochlorperazine, droperidol, promethazine)? Please attach documentation.	
☐ Yes	□ No
Q9. Have all potential contraindications (including conger prolonged QT interval, pregnancy) been excluded?	nital long QT syndrome, arrhythmias associated with
☐ Yes	□ No
Q10. Will Ingrezza be used concurrently with either a moi (CYP3A4) inducer?	noamine oxidase (MAO) inhibitor or strong cytochrome 3A4
☐Yes	□ No
Q11. Additional Information:	
Q12. Requested Duration:	
☐ 12 Months	
Prescriber Signature	Date
	2022 Medicare Prior Authorization Reques